BROADCASTS.com

In this episode of the TheoryLab podcast, two American Cancer Society grantees discussed key takeaways from their recent publications. \n\nIn the first part of the conversation, which is intended for a lay audience, Dr. Joshua Andersen and Dr. Bhuminder Singh talked about targeted therapies, treatment side effects, and drug resistance.\n\nThen they moved into a more technical discussion of their recent papers. \n\nDr. Andersen recently published findings showing that \u201cTNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.\u201d\nhttps://doi.org/10.1038/s41467-021-25622-3\n\nDr. Singh published a study recently showing that \u201cInduction of apically mistrafficked epiregulin disrupts epithelial polarity via aberrant EGFR signaling.\u201d\nhttps://doi.org/10.1242/jcs.255927 \n\nJoshua L. Andersen, PhD, is Associate Professor of Biochemistry at Brigham Young University. He is a two-time American Cancer Society grantee. \n\nBhuminder Singh, PhD, is Assistant Professor of Medicine and Cell and Developmental Biology at Vanderbilt University Medical Center, and he is also a two-time American Cancer Society grantee.\n\n1:25 \u2013 Dr. Andersen explains why his lab is focused on improving targeted therapies\n\n2:31 \u2013 Dr. Singh describes how his research is focused on addressing drug resistance in colorectal cancer\n\n4:28 \u2013 Dr. Andersen dives into his lab\u2019s new Nature Communications paper on a new cancer driver\u2014"it\u2019s been probably the most rewarding project that I\u2019ve been a part of in my career\u201d\n\n8:11 \u2013 Dr. Singh asks a few questions about the paper: \u201cAre there any mutations in TNK1 in human cancer?\u201d\n\n10:01 \u2013 What ubiquitinated proteins was it binding to?\n\n11:44 \u2013 Is TNK1 itself ubiquitinated in certain conditions?\n\n12:49 \u2013 Dr. Singh explains takeaways from his paper, \u201cInduction of apically mistrafficked epiregulin disrupts epithelial polarity via aberrant EGFR signaling\u201d\n\n19:16 \u2013 Follow-up questions from Dr. Andersen: \u201cHow could the mistrafficking of a single ligand affect its localization so dramatically?\u201d\n\n22:04 \u2013 \u201cThat has to send a signal then to start trafficking the intracellular EGFR out to the apical side of the cell, right?\u201d\n\n27:49 \u2013 \u201cAs someone who hasn\u2019t really thought about cell polarity very much inside a solid tumor, what would be the effects of mistrafficking in terms of the architecture of a solid tumor?\u201d\n\n31:18 \u2013 The impact of American Cancer Society funding on their research